SLEdgehammer
Breaking the vicious autoimmunity cycle in autoimmune diseases
Over 5 million patients worldwide suffer from the chronic autoimmune disease Systemic Lupus Erythematosus, SLE. Today there is a lack of effective treatments for the disease.
SLEdgeHammer is developing a novel drug candidate for treating autoimmune diseases, such as SLE. By modulating two signaling pathways by one molecule, they aim to break the vicious autoimmunity cycle of the disease.
Team & KTH connection
SLEdgeHammer was founded by Johan Rockberg, Julia Rockberg and Aman Mebrahtu. Johan is Professor in Antibody engineering and Directed evolution at KTH. Julia and Aman both hold PhDs in molecular biotechnology from KTH.